FDA clears ID Biomedical to seek accelerated approval for Fluviral

The U.S. FDA has given ID Biomedical of Canada clearance to seek accelerated approval for its flu vaccine, enabling the firm to begin marketing Fluviral as early as the 2006 flu season. Some potential investors believe the company could still enter the U.S. market this winter if Chiron fails to return its vaccine to the market in time.

View Full Article in:

Globe and Mail (Toronto) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Chicago, IL
Senior Manager, Compliance
Fremont, CA
Manager, Business Conduct
Foster City, CA
Product Patent Attorney
Foster City, CA
Employment Counsel
Foster City, CA